Clinical trials: Metastatic Colorectal Cancer, completed
Colorectal Cancer
Phase I/II CT 2106 and 5-FU/FA in Colorectal Cancer
CT-2106, a camptothecin (CPT) conjugate, is a new generation of topoisomerase I inhibitors designed to deliver higher, more effective chemotherapy to tumor tissue with less toxicity to normal tissues.
- Trial name
- NCT00291785
- Testing
- CT-2106, Folinic acid, 5-FU (fluorouracil)
- Where
- 2 sites in Italy
- Volunteers
- 48 people
- Sponsor
- CTI BioPharma
Colorectal Neoplasms
Stivarga Regulatory Post-Marketing Surveillance Study in Korea
To investigate and collect post-marketing data on the safety of Stivarga in real world practice in its registered indication(s) as required by Health Authority.
- Trial name
- StivargaPMS (NCT02106858)
- Testing
- Regorafenib (Stivarga,BAY73-4506)
- Where
- South Korea
- Volunteers
- 316 people
- Sponsor
- Bayer
Colon Adenocarcinoma, High-Frequency Microsatellite Instability
M7824 in Patients With Metastatic Colorectal Cancer or With Advanced Solid Tumors With Microsatellite Instability
This phase Ib/II trial studies how well anti-PD-L1/TGFbetaRII fusion protein M7824 (M7824) works in treating patients with colorectal cancer (or with other solid tumors with microsatellite instability) that has spread to other…
- Conditions
- Colon Adenocarcinoma, High-Frequency Microsatellite Instability, Metastatic Malignant Solid Neoplasm, Rectal Adenocarcinoma
- Trial name
- NCT03436563
- Testing
- Anti-PD-L1/TGFbetaRII Fusion Protein M7824
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- M.D. Anderson Cancer Center
Colorectal Cancer, Non Resectable Metastasis
Response Prediction in Metastasized Colorectal Cancer Using Intratumoral Thymidylate Synthase
The aim of the study was to evaluate the feasibility of TS determination in a multicenter trial setting using a central facility for measurement and confirm its role as predictive factor for 5-FU treatment in MCRC.
- Conditions
- Colorectal Cancer, Non Resectable Metastasis, Reference Lesion, Biopsy
- Trial name
- FOGT5 (NCT01212718)
- Testing
- FUFA, systemic chemotherapy
- Where
- Germany
- Volunteers
- 168 people
- Sponsor
- University of Ulm
Colorectal Cancer, Metastatic Cancer
Combination Chemotherapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving drugs in different ways may kill more tumor cells.
- Trial name
- NCT00006050
- Testing
- FOLFOX regimen, fluorouracil, isolated perfusion
- Where
- 3 sites in France
- Sponsor
- UNICANCER
Adenocarcinoma of Colon, Adenocarcinoma of Rectum
Study of Individualized Therapies Selection for Patients With Metastatic Colorectal Carcinoma According to the Therapeutic
The purpose of this study is to assess the feasibility of selecting personalized therapies for colon cancer patients who have failed standard treatments, using a new methodology based on the determination of a profile of…
- Conditions
- Adenocarcinoma of Colon, Adenocarcinoma of Rectum, Metastatic Disease
- Trial name
- NCT01703910
- Testing
- Arm A chemotherapy, arm B chemotherapy
- Where
- 2 sites in Spain
- Volunteers
- 29 people
- Sponsor
- Centro Nacional de Investigaciones Oncologicas CARLOS III
Metastatic Colorectal Cancer
Study of IMC-11F8 in Participants With Colorectal Cancer
The purpose of this study is to determine if IMC-11F8 in combination with chemotherapy is effective in treating colorectal cancer (CRC).
- Trial name
- NCT00835185
- Testing
- IMC-11F8 (necitumumab), Oxaliplatin, Folinic acid (FA)
- Where
- 5 sites in Belgium, Spain
- Volunteers
- 44 people
- Sponsor
- Eli Lilly and Company
Colorectal Cancer
A Study of Xeloda (Capecitabine) in Combination With Oxaliplatin in Patients With Metastatic Colorectal Cancer.
This single arm study will investigate possible pharmacokinetic interactions between Xeloda and oxaliplatin, and assess whether the pharmacokinetics of Xeloda and/or oxaliplatin is influenced by the addition of Avastin.
- Trial name
- NCT00353262
- Testing
- Avastin, Oxaliplatin, capecitabine [Xeloda]
- Where
- 3 sites in Canada
- Volunteers
- 36 people
- Sponsor
- Hoffmann-La Roche
Colorectal Neoplasms
Aflibercept +/- LV5FU2 in First Line of Non-resectalbe Metastatic Colorectal Cancers
This is what the FFCD 11-01 - PRODIGE 25 trial proposes to study, as a preliminary for strategic studies evaluating the usefulness of including targeted therapeutics from the first line with aflibercept +/- LV5FU2.
- Trial name
- FOLFA (NCT02384759)
- Testing
- aflibercept, LV5FU2
- Where
- 58 sites in France
- Volunteers
- 117 people
- Sponsor
- Federation Francophone de Cancerologie Digestive
Colorectal Carcinoma, Neoplasm Metastasis
CIRSE Registry for LifePearl Microspheres
The application of transarterial chemoembolisation (TACE) using LifePearl Microspheres loaded with Irinotecan in liver-only or liver-dominant metastatic disease in patients with colorectal adenocarcinoma will be observed.
- Trial name
- CIREL (NCT03086096)
- Testing
- LifePearl Microspheres loaded with Irinotecan
- Where
- Austria
- Volunteers
- 152 people
- Sponsor
- Cardiovascular and Interventional Radiological Society of Europe
Colon Cancer, Colorectal Cancer
Panitumumab Regimen Evaluation in Colorectal Cancer to Estimate Primary Response to Treatment
The primary objective is to estimate the effect of the human homolog of the Kirsten rat sarcoma-2 virus oncogene (KRAS) mutation status (wild type versus mutant) from tumor tissue on efficacy endpoints in patients with metastatic…
- Conditions
- Colon Cancer, Colorectal Cancer, Rectal Cancer, Cancer
- Trial name
- PRECEPT (NCT00411450)
- Testing
- Panitumumab, FOLFIRI
- Volunteers
- 116 people
- Sponsor
- Amgen
Metastatic Colon Adenocarcinoma, Metastatic Colorectal Adenocarcinoma
A Vaccine (PolyPEPI1018 Vaccine) and TAS-102 for the Treatment of Metastatic Colorectal Cancer
This phase Ib trial studies the safety and side effects of a vaccine (PolyPEPI1018 vaccine) in combination with TAS-102 in treating patients with colorectal that has spread to other parts of the body (metastatic).
- Conditions
- Metastatic Colon Adenocarcinoma, Metastatic Colorectal Adenocarcinoma, Metastatic Colorectal Carcinoma, Metastatic Microsatellite Stable Colon Carcinoma
- Trial name
- NCT05130060
- Testing
- Colorectal Cancer Peptide Vaccine PolyPEPI1018, Trifluridine and Tipiracil Hydrochloride
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Mayo Clinic
Colorectal Cancer Metastatic
Nab-Sirolimus in Combination With FOLFOX & BEV as 1st Line Therapy in Patients With Advanced or Metastatic Colorectal Cancer
A phase 1/2 multi-center investigation of nab-sirolimus (also known as ABI-009, nab-rapamycin) in combination with mFOLFOX6 and Bevacizumab as first-line therapy in patients with metastatic colorectal cancer
- Trial name
- NCT03439462
- Testing
- nab-sirolimus
- Where
- 6 sites in United States
- Volunteers
- 60 people
- Sponsor
- Aadi Bioscience, Inc.
Colorectal Cancer With Non Resectable Hepatic Metastasis
Intra-arterial Hepatic Beads Loaded With Irinotecan With Concomitant Chemotherapy With FOLFOX in Patients With Colorectal Cancer With Unresectable Liver Metastases: a Phase II Multicenter Study
Treatment of patients with colorectal cancer having liver metastases is currently based on systemic chemotherapy. Triple therapy with 5FU, oxaliplatin and irinotecan intravenously was effective in terms of response and secondary…
- Trial name
- NCT01839877
- Testing
- HIA DEBIRI + systemic FOLFOX
- Where
- 9 sites in France
- Volunteers
- 58 people
- Sponsor
- Federation Francophone de Cancerologie Digestive
Liver Only Metastasis From KRAS Exon 2 Wild Type (Under Protocol 1.0-1.2 Edition) and RAS Wild Type (Under Protocol 2.0 Edition) Colorectal Cancer
Achievement of Improved Survival by Molecular Targeted Chemotherapy and Liver Resection for Not Optimally Resectable Colorectal Liver Metastases
The purpose of this study is to evaluate efficacy and safety of mFOLFOX6+bevacizumab and mFOLFOX6+cetuximab for liver only metastasis from KRAS Exon 2 wild type (under protocol 1.0-1.2 edition) and RAS wild type (under protocol…
- Trial name
- ATOM (NCT01836653)
- Testing
- Bevacizumab, Cetuximab, L-OHP
- Where
- Japan
- Volunteers
- 122 people
- Sponsor
- EPS Corporation
Neoplastic Cells, Circulating
The Detection of Circulating Tumor Cells (CTCs) in Patients With Colorectal Cancer Undergoing Cryosurgery Combined With DC-CIK Treatment
Circulating tumor cells (CTCs) have the potential to provide a surrogate for'real-time biopsy' of tumor biological activity. Enumeration and molecular characterization of CTCs in colorectal cancer could play an important role in…
- Trial name
- NCT02450422
- Testing
- Flow cytometry (FCM), RT-PCR
- Where
- China
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Fuda Cancer Hospital, Guangzhou
Colon Cancer
NGR-hTNF Administered in Combination With a Standard Oxaliplatin Based Regimen in Patients With Metastatic Colorectal Cancer
The main objective of the trial is to document the safety of NGR-hTNF administered at low and high doses in combination with a standard oxaliplatin based regimen in patients with metastatic colorectal cancer not amenable to any…
- Trial name
- NCT00675012
- Testing
- NGR-hTNF, Oxaliplatin, capecitabine
- Where
- Italy
- Volunteers
- 24 people
- Sponsor
- AGC Biologics S.p.A.
Colon Cancer
Bevacizumab and Cetuximab in Combination With FOLFOX6 in Patients With Metastatic Colorectal Cancer
This trial will evaluate the combination of modified infusional 5-fluorouracil/ leucovorin, oxaliplatin (FOLFOX6), bevacizumab, and cetuximab in patients with metastatic colorectal cancer.
- Trial name
- NCT00193219
- Testing
- Bevacizumab, Cetuximab, 5-fluorouracil
- Where
- 10 sites in United States
- Volunteers
- 36 people
- Sponsor
- SCRI Development Innovations, LLC
Colorectal Cancer
Safety Study of Regorafenib With PF-03446962 to Treat Colorectal Cancer
The primary objective of this open-label phase Ib trial is to determine the maximum tolerated dose and the recommended phase II dose for the combination of PF-03446962 plus regorafenib in patients with metastatic colorectal…
- Trial name
- REGAL-1 (NCT02116894)
- Testing
- PF-03446962, Regorafenib
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Duke University
Colorectal Cancer
Low Dose Metronomic Poly-chemotherapy for Metastatic CRC
This study investigates the activity of a new regimen of treatment for patients with metastatic colorectal carcinoma. This includes a combination of well-known chemotherapy agents and anti-inflammatory agents, when administered…
- Trial name
- LDMchemoCRC (NCT02280694)
- Testing
- Capecitabine, Cyclophosphamide, Methotrexate
- Where
- Israel
- Volunteers
- 45 people
- Sponsor
- HaEmek Medical Center, Israel
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.